Predictive diagnostics developer KIYATEC has partnered with Greenville Health System (GHS) Cancer Institute to study its new range of diagnostic tests to predict the response of ovarian cancer patients to chemotherapy before providing treatment.
Within next year, the organisations plan to extend the clinical studies of the tests to patients suffering from other types of cancer.
Results from the study will be used to inform treatment decisions and gain a better understanding of the potential success of these treatments.
The predictive tests are also expected to minimise the stress and pain caused due to less information on the patient-specific response.
During the studies, a patient’s cancer cells will be transferred to a three-dimensional (3D) cell culture at the KIYATEC laboratories.
The 3D cultures, which are designed to accurately reproduce the biologic and physiologic interactions of natural human cells, will be treated with different chemotherapies and cancer-treatment drugs.
Various concentrations of the therapies will be assessed to establish a cell’s drug response level, which will then be used to predict patient responsiveness to a specific treatment.
KIYATEC CEO Matthew Gevaert said: “Human cells are as unique as the patients themselves, so you really need to see the way those cells interact with given drugs to know for certain what treatment will work.
“By placing each patient’s cancer cells in conditions that mimic the actual human body, we can drill down to drug effect on the cellular level and establish the connection between the results we see in the lab and the response we hope to see in the patients.”